Purpose of this Study
We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.
Who Can Participate?
Eligibility
Adults ages 18+ who are diagnosed with one of the following types of cancer that is advanced or metastatic:
- Hepatocellular carcinoma (HCC); OR
- Biliary tract cancer (BTC); OR
- Pancreatic ductal adenocarcinoma (PDAC); OR
- Esophageal squamous cell carcinoma (ESCC); OR
- Triple-negative breast cancer (TNBC); OR
- HR-positive and HER2-negative breast cancer (HR+/HER-); OR
- Head and neck squamous cell carcinoma (HNSCC)
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
- Hepatocellular carcinoma (HCC); OR
- Biliary tract cancer (BTC); OR
- Pancreatic ductal adenocarcinoma (PDAC); OR
- Esophageal squamous cell carcinoma (ESCC); OR
- Triple-negative breast cancer (TNBC); OR
- HR-positive and HER2-negative breast cancer (HR+/HER-); OR
- Head and neck squamous cell carcinoma (HNSCC)
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, you will:
- Get the study drug through an IV once every 3 weeks
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
- Get the study drug through an IV once every 3 weeks
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Study Details
Full Title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Principal Investigator
John
Strickler
Protocol Number
PRO00113960
NCT ID
NCT06084481
Phase
I
Enrollment Status
OPEN TO ACCRUAL